The camptothecins

被引：342

作者：

Pizzolato, JF ^{[1
]}

Saltz, LB ^{[1
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, Gastrointestinal Oncol Serv, New York, NY 10021 USA

来源：

LANCET | 2003年 / 361卷 / 9376期

关键词：

D O I：

10.1016/S0140-6736(03)13780-4

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Supported by detailed understanding of their mechanism of action, and facilitated by chemical manipulations that have amplified their solubility, the camptothecins have advanced to the forefront of several areas of therapeutic and developmental chemotherapy. Additive and synergistic laboratory interactions with other cytotoxic drugs have been exploited to allow development of camptothecin-based multidrug regimens, which are showing important activity in several malignancies. Topotecan and irinotecan are already in widespread use in clinical practice, and newer agents with promising preclinical activity are in various stages of clinical assessment. As knowledge of molecular and biochemical mechanisms of action and resistance continues to expand, newer and better camptothecin-based strategies for treatment of malignant disease are likely to evolve.

引用

页码：2235 / 2242

页数：8

共 94 条

[1] IRINOTECAN (CPT-11) HIGH-DOSE ESCALATION USING INTENSIVE HIGH-DOSE LOPERAMIDE TO CONTROL DIARRHEA [J].

ABIGERGES, D ;

ARMAND, JP ;

CHABOT, GG ;

DACOSTA, L ;

FADEL, E ;

COTE, C ;

HERAIT, P ;

GANDIA, D .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1994, 86 (06) :446-449

[2]

ABOUALFA GK, P AM SOC CLIN ONC 20

[3] Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: A phase II study in patients with refractory and sensitive disease [J].

Ardizzoni, A ;

Hansen, H ;

Dombernowsky, P ;

Gamucci, T ;

Kaplan, S ;

Postmus, P ;

Giaccone, G ;

Schaefer, B ;

Wanders, J ;

Verweij, J .

JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (05) :2090-2096

[4] EFFECTS OF ACETORPHAN, AN ENKEPHALINASE INHIBITOR, ON EXPERIMENTAL AND ACUTE DIARRHEA [J].

BAUMER, P ;

DORVAL, ED ;

BERTRAND, J ;

VETEL, JM ;

SCHWARTZ, JC ;

LECOMTE, JM .

GUT, 1992, 33 (06) :753-758

[5]

Beran M, 1998, SEMIN HEMATOL, V35, P26

[6]

BLANKE CD, P AM SOC CLIN ONC 20

[7] Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer [J].

Boku, N ;

Ohtsu, A ;

Shimada, Y ;

Shirao, K ;

Seki, S ;

Saito, H ;

Sakata, Y ;

Hyodo, I .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (01) :319-323

[8] Developmental chemotherapy in advanced ovarian cancer: Incorporation of newer cytotoxic agents in a phase III randomized trial of the Gynecologic Oncology Group (GOG-0182) [J].

Bookman, MA .

SEMINARS IN ONCOLOGY, 2002, 29 (01) :20-31

[9] POPULATION PHARMACOKINETICS AND PHARMACODYNAMICS OF IRINOTECAN (CPT-11) AND ACTIVE METABOLITE SN-38 DURING PHASE-I TRIALS [J].

CHABOT, GG ;

ABIGERGES, D ;

CATIMEL, G ;

CULINE, S ;

DEFORNI, R ;

EXTRA, JM ;

MAHJOUBI, H ;

HERAIT, P ;

ARMAND, JP ;

BUGAT, R ;

CLAVEL, M ;

MARTY, ME .

ANNALS OF ONCOLOGY, 1995, 6 (02) :141-151

[10] Oral topotecan as single-agent second-line chemotherapy in patients with advanced ovarian cancer [J].

Clarke-Pearson, DL ;

Van Le, L ;

Iveson, T ;

Whitney, CW ;

Hanjani, P ;

Kristensen, G ;

Malfetano, JH ;

Beckman, RA ;

Ross, GA ;

Lane, SR ;

DeWitte, MH ;

Fields, SZ .

JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (19) :3967-3975

← 1 2 3 4 5 6 7 8 9 10 →